aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
05 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
29 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
27 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
26 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
Topline results are expected in the fourth quarter of 2020. Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment. SAN DIEGO, Oct. 26, 2020 (GLOBE...
aTyr Pharma to Participate in October Virtual Investor Events
07 oct. 2020 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
15 sept. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at September Investor Conferences
09 sept. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
13 août 2020 16h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan
11 août 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
22 juin 2020 08h00 HE
|
aTyr Pharma, Inc.
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN...